Inhibition of FXa could be a novel therapeutic target associated with hypoxia-associated tumor behavior?
The findings of this study suggest that Rivaroxaban has the potential to be both an effective anticoagulant and an anticancer agent against CRC under both hypoxic and normoxic conditions. This paper puts forward an alternative utilization method for Rivaroxaban.
Authors
- Serdar Bayrak
- Yasemin Başbınar (ORCID: https://orcid.org/0000-0001-9439-2217)
- Özge Bayrak (ORCID: https://orcid.org/0000-0002-6223-1272)
- Nazli Mert-Ozupek (ORCID: https://orcid.org/0000-0002-1627-1548)
Institutions
- Dokuz Eylül University (TR)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1007/s12672-025-02403-8
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
- Dokuz Eylül Üniversitesi
- Yükseköğretim Kurulu